Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals Abstract #1208

Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.
Aim(s): To assess the pt perspective on NET management and interactions with healthcare professionals (HCPs).
Materials and methods: Anonymous survey of NET pts from >12 countries conducted by INCA/Novartis in 2014 (Americas, Asia, Europe, Oceania) on the NET pt experience, including NET management and interactions with HCPs. All comparisons are significant at the P<0.05 level. This NET patient survey was a collaboration between INCA and Novartis and the survey was funded by Novartis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Professor Kjell Öberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Professor Marianne Pavel
Keywords: Diagnosis
#2775 Glucagonoma: Still a Misleading Disease and the Importance of Multidisciplinary Neuroendocrine Tumor Board
Introduction: Glucagonoma is a rare neuroendocrine tumor (NET) of the pancreatic alpha cells that results in the overproduction of the hormone glucagon. This entity is typically associated with a rash called necrolytic migratory erythema, weight loss and diabetes.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#2928 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis
Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Teodora Kolarova